CYP2C19 METABOLIZER PHENOTYPE PREDICTS SERTRALINE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS

被引：0
|
作者：
Poweleit, Ethan [1 ]
Vaughn, Samuel [2 ]
Desta, Zeruesenay [3 ]
Strawn, Jeffrey [1 ]
Ramsey, Laura [2 ]
机构：
[1] Univ Cincinnati, Cincinnati, OH 45221 USA
[2] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
[3] Indiana Univ, Bloomington, IN 47405 USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2021年 / 51卷
关键词：
D O I：
10.1016/j.euroneuro.2021.08.070
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
TU68
引用
收藏
页码：E132 / E132
页数：1
相关论文
共 50 条
  • [1] CYP2C19 Metabolizer Status Predicts Sertraline and Escitalopram Pharmacokinetics in Children and Adolescents
    Poweleit, Ethan
    Vaughn, Samuel
    Desta, Zeruesenay
    Ramsey, Laura
    Strawn, Jeffrey
    [J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 154 - 154
  • [2] CYP2C19 METABOLIZER PHENOTYPE INFLUENCES SERTRALINE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS.
    Vaughn, S.
    Poweleit, E.
    Desta, Z.
    Strawn, J.
    Ramsey, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S54 - S54
  • [3] CYP2C19 METABOLIZER STATUS PREDICTS ESCITALOPRAM PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Vaughn, Sam
    Poweleit, Ethan
    Desta, Zeruesenay
    Strawn, Jeffrey
    Ramsey, Laura
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2021, 60 (10): : S215 - S215
  • [4] CYP2C19 METABOLIZER STATUS PREDICTS ESCITALOPRAM PHARMACOKINETICS IN ADOLESCENTS WITH GENERALIZED ANXIETY DISORDER
    Tulisiak, Anne K.
    Poweleit, Ethan
    Ramsey, Laura A.
    Mills, Jeffrey A.
    Varney, Sara T.
    Mossman, Sarah
    Schroeder, Heidi K.
    Delbello, Melissa P.
    Strawn, Jeffrey Robert
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2019, 58 (10): : S247 - S247
  • [5] CYP2D6 METABOLIZER PHENOTYPE PREDICTS ARIPIPRAZOLE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Hiken, Eliah J.
    Poweleit, Ethan A.
    Keane, Corey
    Desta, Zeruesenay
    Strawn, Jeffrey R.
    Ramsey, Laura B.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2023, 62 (10): : S197 - S197
  • [6] CYP2C19 PHENOTYPE AND ADVERSE EVENTS DURING SERTRALINE TREATMENT IN CHILDREN AND ADOLESCENTS.
    Neely, K.
    Aka, I.
    Maxwell-Horn, A.
    Roden, D.
    Van Driest, S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S56 - S56
  • [7] CYP2C19 PHENOTYPE AND ADVERSE EVENTS DURING SERTRALINE TREATMENT IN CHILDREN AND ADOLESCENTS.
    Neely, K.
    Aka, I.
    Maxwell-Horn, A.
    Roden, D.
    Van Driest, S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S17 - S17
  • [8] Sertraline dosing trends in children and adolescents stratified by CYP2C19 genotype
    Brown, Jacob T.
    Gregornik, David B.
    Jorgenson, Alissa
    Watson, Dave
    Roiko, Samuel A.
    Bishop, Jeffrey R.
    [J]. PHARMACOGENOMICS, 2022, 23 (04) : 247 - 253
  • [9] Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
    Wang, JH
    Liu, ZQ
    Wang, W
    Chen, XP
    Shu, Y
    He, N
    Zhou, HH
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (01) : 42 - 47
  • [10] Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype
    Lang, Jason E.
    Holbrook, Janet T.
    Mougey, Edward B.
    Wei, Christine Y.
    Wise, Robert A.
    Teague, W. Gerald
    Lima, John J.
    [J]. ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 (06) : 878 - 885
12345